Prevalence of multidrug resistance in Mycobacterium tuberculosis isolates from HIV seropositive and seronegative patients with pulmonary tuberculosis in north India

BMC Infectious Diseases

Meera Sharma¹  Ajay Wanchu²  Dheeraj Gupta³  Khushwinder Singh¹  Rakesh Yadav¹  Harpal Singh¹  Sunil Kumar Dhatwalia¹  Abhishek Mewara¹  Sunil Sethi¹ 

[1] Department of Medical Microbiology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India;Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India;Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India

关键词: Socioeconomic status;    HIV;    Extensively-drug resistant;    Multidrug resistant;    Mycobacterium tuberculosis;   

Others  :  1175127
DOI  :  10.1186/1471-2334-13-137

 received in 2012-04-19, accepted in 2013-03-04,  发布年份 2013

【 摘 要 】

Background

Multidrug resistant (MDR) and extensively-drug resistant (XDR) tuberculosis (TB) are a serious threat to the national TB control programs of developing countries, and the situation is further worsened by the human immunodeficiency virus (HIV) pandemic. The literature regarding MDR/XDR-TB is, however, scanty from most parts of India. We carried out this study to assess the prevalence of MDR/XDR-TB in new and previously treated cases of pulmonary TB and in HIV seropositive and seronegative patients.

Methods

Sputum and blood specimens were obtained from 2100 patients suspected of pulmonary tuberculosis and subjected to sputum microscopy and culture for TB, and HIV serology at our tertiary care centre in north India. The culture positive Mycobacterium tuberculosis isolates were subjected to drug susceptibility testing (DST) for first line anti-tuberculosis drugs, and the MDR isolates were further subjected to second line DST. Various parameters of the patients’ were analyzed viz. clinical presentation, radiology, previous treatment history, demographic and socioeconomic data and microbiology results.

Results

Of the 2100 patients, sputum specimens of 256 were smear positive for acid-fast bacilli (AFB), 271 (12.9%) grew Mycobacterium spp., and M. tuberculosis was isolated in 219 (10.42%). Of the 219 patients infected with M. tuberculosis, 20.1% (44/219) were found to be seropositive for HIV. Overall, MDR-TB was observed in 17.4% (39/219) isolates. There were 121 newly diagnosed and 98 previously treated patients, of which MDR-TB was found to be associated with 9.9% (12/121) and 27.6% (27/98) cases respectively. There was significantly higher association of MDR-TB (12/44, 27.3%) with HIV seropositive patients as compared to HIV seronegative patients (27/175, 15.4%) after controlling previous treatment status, age, and sex (odd’s ratio, 2.3 [95% CI, 1.000-5.350]; p-value, 0.05). No XDR-TB was found among the MDR-TB isolates.

Conclusion

The present study demonstrated a high prevalence of drug resistance amongst pulmonary TB isolates of M. tuberculosis from north India as compared to the WHO estimates for India in 2010, though this could possibly be attributed to the clustering of more serious or referred cases at our tertiary care centre. The prevalence of MDR-TB in HIV seropositive patients was significantly higher than seronegative individuals. The study emphasizes the need to monitor the trends of drug resistance in TB in various populations in order to timely implement appropriate interventions to curb the menace of MDR-TB.

【 授权许可】

   
2013 Sethi et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]World Health Organization: Global Tuberculosis Control: WHO report 2011. Available: http://www.who.int/tb/publications/global_report/2011/gtbr11_full.pdf webcite. Accessed 26 March, 2013
• [2]World Health Organization: Multidrug and extensively drug-resistant TB (M/XDR-TB): 2010 global report on surveillance and respons. Available: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf webcite. Accessed 26 March, 2013
• [3]Thaiss WM, Thaiss CC, Thaiss CA: Recent developments in the epidemiology and management of tuberculosis – new solutions to old problems? Infect Drug Resist 2012, 5:1-8.
• [4]Paramasivan CN: An overview of drug resistant tuberculosis in India. Ind J Tuberc 1998, 45:73-81.
• [5]Paramasivan CN, Venkataraman P: Drug resistance in tuberculosis in India. Indian J Med Res 2004, 120:377-386.
• [6]Chauhan LS: Drug resistant TB-RNTCP response (P.K. Sen-TAI Gold Medal oration delivered at the 62nd National Conference on Tuberculosis & Chest Diseases held in New Delhi from 14th to 16th December, 2007). Indian J Tuberc 2008, 55(1):5-8.
• [7]National AIDS Control Organization, India: NACO Guidelines on HIV testing. Available: http://nacoonline.org/upload/Policies%20%20Guidelines/5-GUILDELINES%20FOR%20HIV%20TESTING.pdf webcite. Accessed 26 March, 2013
• [8]Vestal AL: Procedures for isolation and identification of Mycobacteria. CDC Atlanta, Georgia: U.S. Department of Health, Education and Welfare, Publication No CDC-77-8230; 1997:15-19.
• [9]Canetti G, Froman F, Grosset J, Hauduroy P, Langerova M, Mahler HT, Meissner G, Mitchison DA, Sula L: Mycobacteria: laboratory methods for testing drug sensitivity and resistance. Bull. WHO 1963, 41:21-43.
• [10]Rüsch-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S: Multicenter laboratory validation of the BACTEC MGIT 960 technique for testing susceptibilities of mycobacterium tuberculosis to classical second-line drugs and newer antimicrobials. J Clin Microbiol 2006, 44(3):688-692.
• [11]Sharma SK, Kaushik G, Jha B, George N, Arora SK, Gupta D, Singh U, Hanif M, Vashisht RP: Prevalence of multidrug-resistant tuberculosis among newly diagnosed cases of sputum-positive pulmonary tuberculosis. Indian J Med Res 2011, 133:308-311.
• [12]Jain NK, Chopra KK, Prasad G: Initial and acquired isoniazid and rifampicin resistance to Mycobacterium tuberculosis and its implication for treatment. Indian J Tuberc 1992, 39:12-14.
• [13]D’souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, Nicol M, Wilkinson RJ: High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Publ Health 2009, 9:211. BioMed Central Full Text
• [14]Sharma SK, Kumar S, Saha PK, George N, Arora SK, Gupta D, Singh U, Hanif M, Vashisht RP: Prevalence of multidrug-resistant tuberculosis among Category II pulmonary tuberculosis patients. Indian J Med Res 2011, 133:312-315.
• [15]Vijay S, Bala Sangameshwara VJ, Jagannatha PS, Kumar P: Initial drug resistance among tuberculosis patients under DOTS Programme in Bangalore City. Indian J Tuberc 2004, 51:17-21.
• [16]Shah AR, Agarwal SK, Shah KV: Study of drug resistance in previously treated tuberculosis patients in Gujarat, India. Int J Tuberc Lung Dis 2002, 6(12):1098-1101.
• [17]Hanif M, Malik S, Dhingra VK: Acquired drug resistance pattern in tuberculosis cases at the State Tuberculosis Centre, Delhi, India. Int J Tuberc Lung Dis 2009, 13(1):74-78.
• [18]Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, Zeller K, Andrews J, Friedland G: Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006, 368(9547):1575-1580.
• [19]World Health Organization 2006: Emergence of XDR-TB. WHO concern over extensive drug resistant TB strains that are virtually untreatable. http://www.who.int/mediacentre/news/notes/2006/np23/en/index.html webcite. Accessed 17 January 2012
• [20]Mondal R, Jain A: Extensively drug-resistant Mycobacterium tuberculosis isolates, India. Emerg Infect Dis 2007, 13(9):1429-1431.
• [21]Jain NK, Agnihotri SP, Sharma KK, Gupta S, Gupta P: Extensively Drug resistance (XDR) TB is not always fatal. Indian J Tuberc 2009, 56:48-50.
• [22]Balaji V, Daley P, Anand AA, Sudarsanam T, Michael JS, Sahni RD, Chordia P, George IA, Thomas K, Ganesh A, John KR, Mathai D: Risk factors for MDR and XDR-TB in a tertiary referral hospital in India. PLoS One 2010, 5(3):e9527.
• [23]Samuel NM, Alamelu C, Jagannath K, Rajan B: Detection of HIV infection in pulmonary tuberculosis patients. J Indian Med Assoc 1996, 94(9):331-333.
• [24]Tripathy S, Joshi DR, Mehendale SM, Menon P, Joshi AN: Sentinel survelliance for HIV infection in tuberculosis patients in India. Indian J Tuber 2002, 49:17-20.
• [25]Gupta S, Shenoy VP, Mukhopadhyay C, Bairy I, Muralidharan S: Role of risk factors and socio-economic status in pulmonary tuberculosis: a search for the root cause in patients in a tertiary care hospital, South India. Trop Med Int Health 2011, 16(1):74-78.
• [26]Shetty N, Shemko M, Vaz M, D’souza G: An epidemiological evaluation of risk factors for tuberculosis in south India: a matched case control study. Int J Tuberc Lung Dis 2006, 10(1):80-86.
• [27]Khan QH: Epidemiology of pulmonary tuberculosis in rural Aligarh. Indian J Community Med 2006, 31(1):39-40.